Business
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended March 31, 2025, and provide a clinical programs update on Wednesday, May 14, 2025 at 8:00 a.m. Eastern Time. Conference Call Details Date: May 14, 2025T
About this update from Pds Biotechnology Corporation
[{"type":"image","alt":"PDS Biotechnology Corporation","displaySize":"","headline":null,"caption":"PDS Biotechnology Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/63fe962c3957c7a225a7c312a7c6913d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6tw_s0aaD8Jse33jriazAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/63fe962c3957c7a225a7c312a7c6913d","width":300,"height":42}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended March 31, 2025, and provide a clinical programs update on Wednesday, May 14, 2025 at 8:00 a.m. Eastern Time.","length":456,"tagName":"p"},{"type":"text","content":"Conference Call Details","length":23,"tagName":"p"},{"type":"text","content":"Date: May 14, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)","length":116,"tagName":"p"},{"type":"text","content":"Webcast Registration: Click HereCall MeTM Registration: Click Here (Available 15 minutes prior to call)","length":104,"tagName":"p"},{"type":"text","content":"After the live webcast, the event will be archived on PDS Biotech’s website for six months.","length":91,"tagName":"p"},{"type":"text","content":"About PDS Biotechnology","length":23,"tagName":"p"},{"type":"text","content":"PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.","length":577,"tagName":"p"},{"type":"text","content":"For more information, please visit www.pdsbiot...